CD82
CD82, also known as KAI1, TSPAN27, R2, IA4 and ST6, is a tetraspanin membrane glycoprotein that organises tetraspanin-enriched microdomains at the cell surface. It acts as a metastasis suppressor and regulates signalling, adhesion, migration and trafficking. Browse Assay Genie's current range of CD82 research reagents below, or read on for the biology behind the target.
CD82 is a structural component of tetraspanin-enriched microdomains (TERMs), specialised membrane platforms for receptor clustering and signalling. Through these microdomains it takes part in signal transduction, adhesion, migration and protein trafficking. It attenuates EGF signalling by facilitating ligand-induced endocytosis and desensitisation of EGFR, modulating EGFR ubiquitination and trafficking via PKC-dependent phosphorylation of the E3 ligase CBL. It also regulates integrin organisation: it increases cell-matrix adhesion through integrin alpha4 (ITGA4), and modulates adhesion and suppresses migration through integrins such as alpha6 (ITGA6) and beta1 (ITGB1).
The protein also acts in immunity and angiogenesis. CD82 associates with CD4 or CD8 and delivers costimulatory signals to the TCR/CD3 pathway. It controls the interaction between TLR9 and VAMP3 during TLR9 trafficking to CpG-containing compartments, and it limits LPS-induced inflammation by preventing LPS binding to TLR4. It contributes to macrophage activation into anti-inflammatory phenotypes and is recruited to pathogen-containing phagosomes before lysosome fusion, supporting antigen presentation. In addition, it binds and sequesters VEGFA and PDGFB, inhibiting their signalling and pushing the angiogenic milieu towards quiescence. It also reduces cell-associated plasminogen activation by interfering with PLAU binding to PLAUR.
The CD82 gene belongs to the tetraspanin (TM4SF) family and the CD molecule gene group. Its expression is downregulated during tumour progression in human cancers and can be activated by p53 through a consensus binding sequence in its promoter. Expression of CD82 and p53 is strongly correlated, and loss of both is associated with poor survival in prostate cancer. The name KAI1 derives from kangai 1, suppression of tumorigenicity 6, prostate. Two alternatively spliced transcript variants encode distinct isoforms.
CD82 expression falls during tumour progression and is linked to p53, and loss of both is associated with poor survival in prostate cancer.
CD82 is a structural component of TERMs, which act as platforms for receptor clustering and signalling.
CD82 attenuates EGF signalling by promoting EGFR endocytosis, and influences TLR9 trafficking and integrin organisation.
CD82 provides T cell costimulation, limits TLR4 responses to LPS, aids antigen presentation, and sequesters VEGFA and PDGFB.
CD82 is a tetraspanin that structures tetraspanin-enriched microdomains, which cluster receptors for signalling. It regulates adhesion and migration through integrins, attenuates EGF signalling by promoting EGFR endocytosis, and contributes to T cell costimulation, TLR trafficking, antigen presentation and control of angiogenesis.
CD82 is also called KAI1, TSPAN27, R2, IA4 and ST6. Previous names include kangai 1 (suppression of tumorigenicity 6, prostate) and CD82 antigen, the R2 leukocyte antigen detected by monoclonal antibody IA4. Two splice variants encode distinct isoforms.
CD82 is a metastasis suppressor whose expression is downregulated in tumour progression and can be activated by p53. Loss of CD82 and p53 is associated with poor survival in prostate cancer. Mouse and rat both have a Cd82 ortholog; check the datasheet of any product for its validated reactivity.
Other CD molecules, tetraspanins, and receptor and signalling partners of CD82 with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P27701; product specifications from Assay Genie datasheets.